HPV vaccination practice

Abstract

Cervical cancer is the third most common gynecological cancer type in the world and approximately 500.000 women diagnosed as cervical cancer, annually. Human papilloma virus (HPV)-DNA presence was showed in about 95% of the cervical cancer cases. There are two types of over-the-counter HPV vaccine approved by Food and Drug Administration (FDA) named as bivalent and quadrivalent vaccine. World Health Organization (WHO), recommends HPV vaccination in order to prevent cervical cancer cases. Due to higher rates of HPV infection during the beginning of sexually active periods of life, vaccination is recommended prior to HPV infection. Most of the developed countries select individuals between 12-17 years of age as the target population in the national vaccination program. According to 2010 data, 33 countries in the world implemented national HPV vaccination program, however most of the countries where cervical cancer incidence is high do not have a vaccination program and policy.